Court Issues Summary Ruling Favoring Pfizer in Patent Dispute
The decision concerned Teva's Abbreviated New Drug Application (ANDA) for Pfizer's blood pressure medicine Accupril. The brand version of the medicine has annual sales of about $600 million.
The US District Court of New Jersey granted Pfizer's motions for a summary judgment of both infringement and validity of several claims of the Accupril formulation patent, which expires in 2007, the company said in a statement issued Tuesday.
The court left the issue...
To view the full article, register now.